Search Results - "Dimopoulos, Meletios-Athanasios"

Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus.

Authors: Spiliopoulou, Polyxeni Eleutherakis-Papaiakovou, Evangelos Migkou, Magdalini et al.

Source: Sports (2075-4663). Feb2026, Vol. 14 Issue 2, p61.

Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First‐Line Treatment.

Authors: Spiliopoulou, Polyxeni Rousakis, Pantelis Panteli, Chrysanthi et al.

Source: Scandinavian Journal of Medicine & Science in Sports (John Wiley & Sons, Inc.). Feb2025, Vol. 35 Issue 2, p1-9.

Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies.

Authors: Theodorakakou, Foteini Fotiou, Despina Spiliopoulou, Vasiliki et al.

Source: Amyloid. Jun2025, Vol. 32 Issue 2, p193-195. 3p.

Remission of recurrent systemic capillary leak syndrome associated with monoclonal gammopathy following anti-myeloma treatment – a case report and literature review.

Authors: Gavriatopoulou, Maria Karamouzis, Konstantinos Katsadouros, Ilias et al.

Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 14, p2774-2777. 4p.

Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression.

Authors: Svarna, Anna Liontos, Michalis Goula, Kallirroi et al.

Source: Current Oncology. Mar2026, Vol. 31 Issue 3, p132. 12p.

Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice.

Authors: Ntanasis-Stathopoulos, Ioannis Koutoulidis, Vassilis Malandrakis, Panagiotis et al.

Source: Journal of Clinical Medicine. Apr2025, Vol. 14 Issue 7, p2224. 9p.

The Role of the Bone Marrow Microenvironment in Physical Function and Quality of Life in Patients with Multiple Myeloma After First-Line Treatment with Novel Agents and Autologous Transplantation.

Authors: Spiliopoulou, Polyxeni Rousakis, Pantelis Panteli, Chrysanthi et al.

Source: Onco. Jun2025, Vol. 5 Issue 2, p21. 14p.

Isolated Leptomeningeal Carcinomatosis in Triple-Negative Breast Cancer: A Case Report.

Authors: Karaferi, Marilena Papatheodoridi, Alkistis Zografos, Eleni et al.

Source: Case Reports in Oncology. 2025, Vol. 18 Issue 1, p1336-1343. 8p.

Author Index: International Journal of Urology 2005.

Source: International Journal of Urology. Dec2005, Vol. 12 Issue 12, p1089-1097. 9p.

This result is not displayed to guests.
Login for full access.

An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.

Authors: Kapoor, Prashant Nathwani, Nitya Jelinek, Tomas et al.

Source: European Journal of Haematology. Nov2024, Vol. 113 Issue 5, p593-605. 13p.

Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis.

Authors: Fotiou, Despina Theodorakakou, Foteini Malandrakis, Panagiotis et al.

Source: Leukemia & Lymphoma. Jun2023, Vol. 64 Issue 6, p1212-1215. 4p.

Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors: Ntanasis-Stathopoulos, Ioannis Filippatos, Charalampos Malandrakis, Panagiotis et al.

Source: Cancers. Jun2025, Vol. 17 Issue 12, p1943. 16p.

Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer.

Authors: Fragkiadaki, Vasiliki Ntanasis-Stathopoulos, Ioannis Liontos, Michalis et al.

Source: Journal of Clinical Medicine. Jun2025, Vol. 14 Issue 11, p3828. 12p.

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.

Authors: Fotiou, Despina Dimopoulos, Meletios Athanasios Kastritis, Efstathios

Source: Cancers. 12/15/2022, Vol. 14 Issue 24, p6216. 18p.

Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis.

Authors: Dimopoulos, Meletios Athanasios Pouli, Anastasia Anagnostopoulos, Athanasios et al.

Source: Leukemia & Lymphoma. Aug2006, Vol. 47 Issue 8, p1553-1556. 4p. 2 Charts, 1 Graph.

Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies.

Authors: Andrikopoulou, Angeliki Zagouri, Flora Goula, Kallirroi et al.

Source: BMC Cancer. 12/5/2024, Vol. 24 Issue 1, p1-8. 8p.

Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.

Authors: Eleutherakis Papaiakovou, Evangelos Terpos, Evangelos Kanellias, Nikolaos et al.

Source: Leukemia & Lymphoma. Dec2023, Vol. 64 Issue 13, p2140-2147. 8p.

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.

Authors: Terpos, Evangelos Zagouri, Flora Liontos, Michalis et al.

Source: Journal of Hematology & Oncology. 5/31/2021, Vol. 14 Issue 1, p1-4. 4p.

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.

Authors: Perrot, Aurore Delimpasi, Sosana Spanoudakis, Emmanouil et al.

Source: Leukemia & Lymphoma. Jun2024, Vol. 65 Issue 6, p833-842. 10p.